Analysis of Biliodigestive Anastomosis Techniques (BDA)
Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Jan 15, 2016
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
The aim of this prospective randomized controlled study is to determine the benefit-risk ratio (success rate, complication rate, tolerance) for patients with biliodigestive anastomosis by either continuous or interrupted suture. A biliodigestive anastomosis is a surgical connection between the common bile duct (ductus choledochus) and the digestive tract to prevent interference of bile flow. Indications for a biliodigestive anastomosis include total or partial resection of the pancreas and duodenum (PPPD, Whipple procedure) for pancreatic tumors, tumors of the biliary tract or duodenum, and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years of age
- • Scheduled for elective BDA procedure
- • Primary BDA procedure
- • Diameter of DHC \> 7mm
- • Written consent
- Exclusion Criteria:
- • Previous BDA procedure
- • Impaired mental state or language problems
- • Lacking compliance
- • Emergency procedure
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dresden, , Germany
Patients applied
Trial Officials
Christoph Reißfelder, MD
Principal Investigator
christoph.reissfelder@uniklinikum-dresden.de
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials